CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Hamlet Pharma is advancing innovative cancer treatments using a peptide derived from human breast milk to selectively target and kill tumor cells. Their lead candidate, Alpha1H, is aimed at early-stage bladder cancer, promising high efficacy with minimal toxicity.
Novel cancer treatments should ideally combine efficacy with selectivity.
Tissue toxicity and side-effects are still the norm, however.
Although new targeted therapies act with greater precision, the notion of tumour-specific cell death is justly regarded with scepticism.
The Swedish company Hamlet Pharma provides new cancer treatments based on a peptide-based molecular approach for targeting and killing tumour cells with greater precision.
Its proprietary drug complex, HAMLET (‘Human Alpha-lact…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, MALMO
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
